See more : Ormat Technologies, Inc. (HNM.DE) Income Statement Analysis – Financial Results
Complete financial analysis of Cadrenal Therapeutics, Inc. Common Stock (CVKD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cadrenal Therapeutics, Inc. Common Stock, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- BAIC Motor Corporation Limited (BCCMY) Income Statement Analysis – Financial Results
- Helios and Matheson Analytics Inc. (HMNY) Income Statement Analysis – Financial Results
- ChemX Materials Limited (CMX.AX) Income Statement Analysis – Financial Results
- Seaport Calibre Materials Acquisition Corp. (SCMA) Income Statement Analysis – Financial Results
- ParkerVision, Inc. (PRKR) Income Statement Analysis – Financial Results
Cadrenal Therapeutics, Inc. Common Stock (CVKD)
About Cadrenal Therapeutics, Inc. Common Stock
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | 0.00 | 0.00 |
| Cost of Revenue | 1.98K | 1.27K |
| Gross Profit | -1.98K | -1.27K |
| Gross Profit Ratio | 0.00% | 0.00% |
| Research & Development | 4.08M | 392.86K |
| General & Administrative | 3.55M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 |
| SG&A | 3.55M | 2.31M |
| Other Expenses | 0.00 | 0.00 |
| Operating Expenses | 7.63M | 2.70M |
| Cost & Expenses | 7.63M | 2.70M |
| Interest Income | 249.09K | 0.00 |
| Interest Expense | 17.10K | 107.11K |
| Depreciation & Amortization | 1.98K | 1.27K |
| EBITDA | -8.34M | -6.61M |
| EBITDA Ratio | 0.00% | 0.00% |
| Operating Income | -7.63M | -2.70M |
| Operating Income Ratio | 0.00% | 0.00% |
| Total Other Income/Expenses | -724.24K | -4.01M |
| Income Before Tax | -8.36M | -6.71M |
| Income Before Tax Ratio | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 4.00 |
| Net Income | -8.36M | -6.71M |
| Net Income Ratio | 0.00% | 0.00% |
| EPS | -9.63 | -8.66 |
| EPS Diluted | -9.63 | -8.66 |
| Weighted Avg Shares Out | 868.18K | 775.64K |
| Weighted Avg Shares Out (Dil) | 868.18K | 775.64K |
Cadrenal Therapeutics Highlights Additional Need for a New Vitamin K Antagonist (Tecarfarin) Following Updates from the Recent European Society of Cardiology Congress
Tecarfarin is the only known Novel Vitamin K Antagonist in Development PONTE VEDRA, Fla. , Sept. 5, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart...
Cadrenal Therapeutics Expands Evaluation of Tecarfarin for Patients with Antiphospholipid Syndrome (APS)
NEW YORK , Aug. 30, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) to prevent heart attacks, strokes and deaths due to blood clots in patients...
Cadrenal Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
PONTE VEDRA, Fla. , Aug. 28, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) to prevent heart attacks, strokes and deaths due to blood clots in...
Cadrenal Therapeutics Provides Second Quarter 2023 Corporate Update
PONTE VEDRA, Fla. , Aug. 10, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) to prevent heart attacks, strokes and deaths due to blood clots in...
Cadrenal Therapeutics Expands Focus for Tecarfarin to Patients with Implanted Medical Devices for Heart Diseases
PONTE VEDRA, Fla. , Aug. 1, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company focused on developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) for certain rare medical conditions, today announced that the Company...
Cadrenal Therapeutics Announces Appointment of Robert Lisicki to Board of Directors
PONTE VEDRA, Fla. , July 24, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., ("Cadrenal" or the "Company") (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) for certain rare medical conditions, today announced the appointment...
Cadrenal Therapeutics Announces $7.5 Million Private Placement Priced At-the-Market under Nasdaq Rules
PONTE VEDRA, Fla. , July 12, 2023 /PRNewswire/ -- Cadrenal Therapeutics, Inc., ("Cadrenal" or the "Company") (Nasdaq: CVKD) a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) for certain rare medical conditions, today announced that...
Why Is Cadrenal Therapeutics (CVKD) Stock Up 71% Today?
Cadrenal Therapeutics (NASDAQ: CVKD ) stock is taking off on Wednesday despite a lack of news from the biopharmaceutical company. There have been no new press releases from Cadrenal Therapeutics that explain why its stock is up today.
IPO Round Up of First Half of 2023
Normally, IPO activity gains momentum in the second quarter and peaks in June. This year was no exception.
The 3 Hottest IPOs to Buy Before They Soar
It has been a tough, quiet year in the market for initial public stock offerings (IPOs) which has investors eagerly searching for high potential IPOs. In the global IPO landscape, the first quarter of 2023 witnessed a total of 299...
Source: https://incomestatements.info
Category: Stock Reports